| January 2 |
Prana Announces Completion of Phase IIa Trial of PBT2 in
Alzheimer's Disease Patients |
| January 2 |
OXiGENE Reports Positive Results in Phase 2 Study of Zybrestat in
Platinum-Resistant Ovarian Cancer |
| January 2 |
Marital Status Doesn't Affect Lung Cancer Survival |
| January 2 |
OXiGENE Reports Positive Preclinical Ocular Penetration Data with
Topical Formulation of Zybrestat for Ophthalmology |
| January 2 |
Testosterone May Improve Mental Function, From the Harvard Men's
Health Watch |
| January 3 |
Antigenics Reports Positive Data on QS-21 Stimulon Adjuvant in
Acambis' Influenza A Vaccine |
| January 3 |
AmpliMed Corporation Announces Promising 1-year Survival Data from
Phase I/II Study of Amplimexon in Metastatic Malignant Melanoma |
| January 3 |
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study
of Ophena (ospemifene) to Treat Postmenopausal Vaginal Syndrome |
| January 3 |
Addex Pharmaceuticals - Addex Announces ADX10059 Phase IIa Acute
Anxiety Data |
| January 3 |
Protox Announces Positive Final Results from BPH Study |
| January 3 |
PhytoMedical's Anti-Cancer Compound Effective at Killing Brain
Cancer Cells |
| January 3 |
FDA Receives New Data on Risks of Anemia Drugs |
| January 3 |
Novel Mechanism for Long-Term Learning Identified by Carnegie
Mellon Researchers |
| January 4 |
Genmab Announces HuMax-CD32b Pre-Clinical Program |
| January 4 |
Anadys Pharmaceuticals Announces Positive Results for ANA598 in
Animal Model of Chronic Hepatitis C Virus Infection |
| January 4 |
The International Myeloma Foundation Says Study Shows 90% Overall
Response for Patients with New Revlimid Combination |
| January 4 |
Ambien CR (zolpidem tartrate extended-release) Tablets CIV Improved
Chronic Insomnia in Patients with Co-Morbid Generalized Anxiety
Disorder |
| January 4 |
Treating Severe Pneumonia in Children Can Be Done Safely and
Effectively at Home |
| January 4 |
Chemotherapy Has Safely Improved Long-Term Survival in Women with
Hormone-Resistant Breast Cancer |
| January 4 |
Antipsychotic Drugs Should Not Be Used Routinely to Treat
Aggression in People with Intellectual Disability |
| January 7 |
Amicus Therapeutics Announces Positive Interim Results From Phase 2
Clinical Trial of Plicera for Gaucher Disease |
| January 7 |
OREXIGEN Therapeutics Reports 48-Week Results of Phase IIb Trial of
Empatic to Treat Obesity |
| January 7 |
Biogen Idec and Elan Provide Update on Utilization, Safety and
Total Patient Exposure of Tysabri in Patients with Multiple
Sclerosis |
| January 7 |
Santarus Announces Positive Clinical Results with Zegerid Capsules
in Controlling Gastric Acidity Over 24 Hours |
| January 7 |
Xeloda Combination Therapy in Esophagogastric Cancer Highlighted in
New England Journal of Medicine |
| January 7 |
Not Only Lipids and Inflammation: Insight Into a New Cause of Heart
Attack and Other Vascular Disease |
| January 7 |
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in
a 4-week Combination Study for the Treatment of Chronic Hepatitis C |
| January 7 |
Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at
JP Morgan Healthcare Conference |
| January 7 |
Maxygen Announces Positive Progress in Phase IIa Clinical Trial of
Novel PEG-GCSF |
| January 7 |
Evotec AG (DE) - Phase I Safety and Tolerability Study with EVT 302
Successfully Completed |
| January 7 |
Study of Sugars on Cell Surface Identifies Key Factor in Flu
Infection |
| January 7 |
Oncolytics Biotech Inc. Announces Publication of Research on
Combination Reovirus and Cyclophosphamide Treatment |
| January 7 |
Researchers Uncover an Error in Immature Brain Cells in Lab and
Animal Studies that May Promote the Growth of Some Brain Tumors |
| January 7 |
Confounding Factors Escape Authors of Recent Study Examining
California Numbers of Autistic Children |
| January 8 |
Arena Pharmaceuticals Announces APD668 Initial Clinical Study
Results Suggest Glucose-Dependent Insulinotropic Receptors May
Improve Glucose Control in Patients With Type 2 Diabetes |
| January 8 |
Watson Announces Positive Results From Its Pivotal Study of
Oxybutynin Topical Gel for the Treatment of Overactive Bladder |
| January 8 |
Researchers Use Magnetism to Target Cells to Animal Arteries |
| January 8 |
Sirtris Announces Positive Results with Proprietary Version of
Resveratrol, SRT501, in a Phase 1b Type 2 Diabetes Clinical Study |
| January 8 |
Halozyme Therapeutics Announces Peer-Reviewed Publications of the
INFUSE-LR Clinical Trial Results and Clinical Practice Experience
With Hylenex |
| January 8 |
Incyte to Report Positive Clinical Results from JAK Inhibitor and
11beta-HSD1 Inhibitor Programs and Introduce New Metabolic Program
at JPMorgan Healthcare Conference |
| January 8 |
Emergent BioSolutions Announces That the Final Phase II Clinical
Study Results for Typhoid Vaccine Reaffirms Clinical Endpoints Met;
Immune Response Seen in 97% of Treated Subjects |
| January 8 |
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a
Clinical Trial in Hypertension |
| January 8 |
Pluristem Announces Second Clinical Indication Revascularization
Effect After PLX-PAD Therapy |
| January 8 |
Benezra Report in Nature Biotechnology Validates AngioGenex's Drug
Development Platform by Demonstrating Tumor Suppression Through Id
Protein Inhibition |
| January 8 |
Intercell’s Results on a Novel Pneumococcal Protein-based
Vaccine Published in the Journal of Experimental Medicine |
| January 8 |
Scientists Use Virus to Wipe Out Cancer Cells |
| January 8 |
Javelin Pharmaceuticals' Latest Study of Dyloject Confirms Minimal
Effect on Platelet Function, Differentiating Dyloject from
Ketorolac and Aspirin |
| January 8 |
Newer Meningitis Vaccine Appears Safe and Effective for Infants |
| January 9 |
Microbially Derived Artemisinin Highlighted in American Journal of
Tropical Medicine and Hygiene's Special Malaria Supplement |
| January 9 |
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial
of DG051 for the Prevention of Heart Attack |
| January 9 |
New Data Show Menveo To Be the First Quadrivalent Meningococcal
Vaccine to Provide Immunogenicity in Infants |
| January 9 |
Somaxon Pharmaceuticals Announces Completion of 26-Week Transgenic
Mouse Carcinogenicity Study of Silenor |
| January 9 |
Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity |
| January 9 |
NIDDK Scientists Detect New Epitope on HIV-1 Protein gp41 Using AbD
Serotec-Generated Recombinant Mini-Antibody |
| January 9 |
Celsion Abstract Chosen for Oral Presentation in Award Session at
IHPBA Congress in Mumbai, India |
| January 10 |
OrbusNeich's Genous Bio-engineered R Stent has Lower MACE Rate than
Taxus and Cypher Stents in Clinical Trial |
| January 10 |
Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial
Results of APD791 for the Treatment of Arterial Thrombosis and
Initiates Phase 1b Clinical Trial |
| January 10 |
Solagran Limited (ASX:SLA) Announce Russian Authorities Accept
H.pylori Patent Application |
| January 10 |
Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary
Phase IIb Data in Advanced Non-Small Cell Lung Cancer |
| January 10 |
Autism Risk Higher in People with Gene Variant |
| January 11 |
AIDS Breakthrough Welcome News, Says AHF |
| January 11 |
Ipsen: Second Symposium on Biological Complexity: 'Genes, Circuits
and Behavior' Jointly Organized by the Salk Institute, Nature and
La Fondation Ipsen |
| January 11 |
Most People with Diabetes Should Be Considered for Statin Therapy |
| January 11 |
Cadence Pharmaceuticals Announces Topline Results of Two Phase III
Clinical Trials of Acetavance |
| January 14 |
ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission
Guidance |
| January 14 |
Radiesse More Effective Than Restylane As Reported In a 60-Patient
Clinical Trial |
| January 14 |
Phase III Data Published for Once Monthly Dose of Risedronate to
Treat Postmenopausal Osteoporosis |
| January 14 |
APR Applied Pharma Research S.A. (“APR”) and Labtec
GmbH (“Labtec”) Announce the Successful Completion of
the Pivotal Bioequivalence Study for Their Proprietary Ondansetron
RapidFilm |
| January 14 |
Merck/Schering-Plough Pharmaceuticals Provides Results of the
ENHANCE Trial |
| January 14 |
Nventa Completes Evaluation of Second Cohort in HspE7 Phase 1
Cervical Dysplasia Trial |
| January 14 |
Merck/Schering-Plough Pharmaceuticals Provides Results of the
ENHANCE Trial |
| January 14 |
Nventa Completes Evaluation of Second Cohort in HspE7 Phase 1
Cervical Dysplasia Trial |
| January 14 |
Schering-Plough Reports Top-Line Results of the IDEAL Study |
| January 14 |
Researchers Uncover New Piece to the Puzzle of Human Height |
| January 14 |
International Effort Finds New Genetic Variants Associated with
Lipid Levels, Risk for Coronary Artery Disease |
| January 14 |
Patients Treated with Lipitor Were Significantly Less Likely to
Have a Cardiovascular Event Than Those Treated with Simvastatin,
New Observational Study Shows |
| January 14 |
Progress Report from RVX-208 Phase 1 Clinical Study |
| January 14 |
Roche Responds to Announcement of 'IDEAL' Hepatitis C Trial Results |
| January 15 |
Anthera Announces Preliminary Positive Results From Once-Daily
A-002 Phase II Cardiovascular Trial |
| January 15 |
Rituximab Added to Six Cycles of Chemotherapy Improves Survival in
Elderly Patients with Aggressive |
| January 15 |
POZEN Submits Human Lymphocyte Study for Treximet (Formerly Known
as Trexima) |
| January 15 |
Tolerx Achieves Milestone with Completion of Phase Ib Clinical
Study of TRX1 in Cutaneous Lupus Erythematosus |
| January 15 |
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of
Second Phase 3 Restless Legs Syndrome Trial for XP13512/GSK1838262 |
| January 15 |
Kamada Announces Successful Completion of Phase I Studies With
Aerosolized AAT for the Treatment of Lung Diseases |
| January 15 |
Study Published in the Journal of Vascular and Interventional
Radiology Concludes That Embosphere Microspheres Should Be the
Preferred Agent for Uterine Fibroid Embolization When Compared to
Boston Scientific's Contour SE PVA Microspheres |
| January 16 |
Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor |
| January 16 |
EPIX Pharmaceuticals Announces Updated Results from Phase 2a
Clinical Trial of PRX-03140 in Alzheimer's Disease |
| January 16 |
Inhibiton Therapeutics Provides Update for ICA-1 Compound in-Vitro
Testing in Breast Cancer Cell Lines |
| January 16 |
New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia |
| January 16 |
GelVac Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes
Preclinical Toxicology Studies |
| January 16 |
CeNeRx BioPharma Announces Successful Completion of Phase l
Clinical Program for Novel Antidepressant Agent Tyrima |
| January 16 |
Study Shows Carperitide Significantly Reduces Cardiac Death and
Improves Outcomes in Acute Myocardial Infarction |
| January 16 |
Morria Biopharmaceuticals Plc Announces Preliminary Safety and
Tolerability Results From Its Phase I Clinical Study of MRX-4 in
Allergic Rhinitis Patients |
| January 16 |
Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH |
| January 16 |
Adding Lipitor Early to Effective Blood Pressure Treatment Provided
a Significant Reduction in Heart Attacks or Deaths from Heart
Attacks over Five Years |
| January 16 |
HemoBioTech, Inc. Featured in New Scientist Magazine |
| January 16 |
TRADE NEWS: Agilent Technologies Microarrays Enable Baylor
Researchers to Discover a Mechanism of Genomic ''Errors''
Associated with Certain Diseases |
| January 16 |
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of
Second Phase 3 Restless Legs Syndrome Trial for XP13512/GSK1838262 |
| January 16 |
St. Jude Defines Eye Cancer Gene's Role in Retinal Development |
| January 16 |
Can-Fite and NIH Signed a Continuation of M-CRADA to Further
Investigate CF101 for the Treatment of Uveitis |
| January 17 |
CollaGenex Pharmaceuticals Announces Results of Phase 4 Clinical
Study Showing Oracea Equally Effective as 100 mg Doxycycline in
Treatment of Rosacea |
| January 17 |
Zevalin Combined With High-Dose Chemotherapy and Autologous
Stem-Cell Transplantation (ASCT) Produces High Overall Survival and
Progression-Free Survival Rates in Patients With Relapsed
Non-Hodgkin's Lymphoma |
| January 17 |
No Bones About It |
| January 17 |
New Study Reports Enbrel (Etanercept) Significantly Improved
Moderate to Severe Plaque Psoriasis in Children and Adolescents |
| January 17 |
Insulin News That's Easy To Swallow |
| January 17 |
Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH |
| January 17 |
Quality of Life, As Important As Life Itself |
| January 17 |
Nuvelo Announces Alfimeprase NAPA-2 Acute Peripheral Arterial
Occlusion Data Presentation Webcast and Conference Call |
| January 17 |
Karo Bio Progress in Eprotirome (KB2115) Development |
| January 18 |
The Lancet Publishes Vasogen's ACCLAIM Results |
| January 18 |
Enlarged Prostate Treatment Study Shows Combination of Avodart and
Tamsulosin Provides Greater Benefit Than Either Medication Alone |
| January 18 |
ProMetic and MacoPharma Announce Successful Completion of P-Capt
Prion Reduction Filter Clinical Studies |
| January 18 |
Prana Announces Publication in Neurobiology of Aging Journal |
| January 18 |
Modified-Release Prednisone Reduces Morning Stiffness in Patients
with Rheumatoid Arthritis (CAPRA-1 TRIAL) |
| January 18 |
Non-Specific Immunomodulation Could Be Used to Treat Patients with
Heart Failure (Acclaim Trial) |
| January 18 |
LifeCycle Pharma Announces Transplantation Programs on Track |
| January 18 |
MGI Pharma Announces Results from Study Involving the Dual
Implantation of Gliadel Wafer and Radioactive Seeds for Treatment
of Recurrent Glioblastoma Multiforme |
| January 18 |
Threshold Updates Glufosfamide Clinical Development Program |
| January 18 |
Schering-Plough Canada Reports Top-Line Results of First
Head-to-Head Study in Hepatitis C |
| January 18 |
In Response to a New England Journal of Medicine Article Published
Yesterday and Subsequent Media Coverage, Eli Lilly and Company
Issued the Following Statement: |
| January 18 |
Mayo Clinic Proceedings January Tip Sheet |
| January 22 |
Preclinical Study Published in Cancer Research Demonstrates
Anti-Tumor Activity of Micromet's BiTE Antibody at Well Tolerated
Doses |
| January 22 |
Vyteris Announces First Successful Non-Invasive Delivery of Peptide
Using Smart Patch Technology |
| January 22 |
Insmed Completes External Assessment of Myotonic Muscular Dystrophy
Market |
| January 22 |
Top-Line Data from Oculus Innovative Sciences' Phase II Trial to Be
Presented at DFCon 08 (Diabetic Foot Global Conference) on March
14, 2008 |
| January 22 |
Indevus Reports Additional Positive Phase III Trial Data for Nebido |
| January 22 |
Scientists Discover Why Animal Studies May Lead to Ineffective ALS
Drugs |
| January 22 |
Novel Akt Inhibitor VQD-002 Shown to Reverse Cisplatin Resistance
in Ovarian Cancer |
| January 22 |
PhytoMedical's Patented Anti-Cancer Compounds Kill Lung Cancer
Cells, a Significant New Finding |
| January 22 |
Celera Publishes Three Papers Demonstrating That Carriers of a Gene
Variant are at Elevated Risk of Coronary Heart Disease Which is
Virtually Eliminated by Statin Therapy |
| January 22 |
Phase II Study of Zevalin Consolidation Following Fludarabine and
Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission
Rate and 89 Percent Three-Year Progression Free Survival in
Patients with Previously Untreated Non-Follicular Indolent Lymphoma |
| January 22 |
Synosia Announces Encouraging Results of Proof-of-Concept Clinical
Trial for Epilepsy Drug rufinamide as a Treatment for Mood
Disorders |
| January 22 |
Super-Thin Drug-Free Coating 'Hides' Stent as It Unblocks Heart
Arteries |
| January 22 |
Nanobac Announces European Heart Journal Publication of Association
Between Calcifying Nanoparticles and Aortic Stenosis |
| January 22 |
Ambrilia: Conference call and webcast for Octreotide Phase III
prelimi... |
| January 22 |
Steps Toward Stopping Autoimmune Disease: International Consortium
Identifies Genes Linked to Lupus |
| January 22 |
CeloNova BioSciences Announces Positive Results from European Study
of Embozene Microspheres for Treatment of Uterine Fibroids |
| January 22 |
FibroGen Reports New Research on Development of HIF Prolyl
Hydroxylase Inhibitors Related to Endothelial Progenitor Cells,
Anti-Inflammation, Cytoprotection and Erythropoiesis |
| January 22 |
Study Says Allergy Shots Help Children, Reduce Health Care Costs
BioMedEcon Study, First of its Kind in US, Finds Allergy
Immunotherapy Beneficial Even When Treatment Not Completed |
| January 23 |
Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi
Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV)
Infection |
| January 23 |
Protein Hormone in Body Fat Clue to Breast Cancer Spread |
| January 23 |
Nitec's Phase III Results with Lodotra in RA Published in Current
Issue of The Lancet |
| January 23 |
Sirtris Pharmaceuticals to Present at Keystone Symposia's Diabetes
Mellitus, Insulin Action and Resistance Conference |
| January 23 |
Advaxis to Host Dinner Reception For Members of the Gynecologic
Oncology Group (GOG) |
| January 23 |
pSivida's BrachySil in Pancreatic Cancer Study Results to be
Presented at the ASCO Gastrointestinal Cancers Symposium |
| January 23 |
New Survey Finds Majority of Americans in Pain; Acute Pain
Sufferers Reluctant to Treat |
| January 23 |
Mayo Clinic Study Finds Further Association Between Diabetes and
Pancreatic Cancer |
| January 23 |
Clinical Trial Best Practices: Savvy Marketers Plan Ahead with
Early Communication Strategies |
| January 24 |
BioCryst Updates Peramivir Clinical Development Plan |
| January 24 |
African Americans Should Not Stop Taking Vytorin or Zetia Without
Consulting Their Healthcare Providers |
| January 24 |
Genaera Corporation Presents Promising Preclinical Type 2 Diabetes
Data for Trodusquemine (MSI-1436) at Keystone Symposia |
| January 24 |
Sirtris Pharmaceuticals: Novel, Potent SIRT1 Activator Reduces Fat,
Boosts Endurance and Improves Insulin Sensitivity in a Pre-clinical
Model of Type 2 Diabetes |
| January 24 |
StemCells, Inc. Enters Research Collaboration with Casey Eye
Institute |
| January 24 |
Positive Primary Endpoint from FIRST-STEP Study with Stalevo in
Early Parkinson's Disease |
| January 24 |
KRAS Gene Status May Impact Vectibix (Panitumumab) Efficacy and
Patient Reported Outcomes in Advanced Colorectal Cancer Patients |
| January 24 |
Boston Scientific Comments on New England Journal of Medicine
Article |
| January 24 |
Technology License with Transgene: Product TG4010 Interim Results |
| January 25 |
Genentech and Biogen Idec Announce Positive Results from a Phase
III Trial of Rituxan in Patients with Rheumatoid Arthritis Who
Inadequately Responded to Methotrexate |
| January 25 |
Merck and Schering-Plough Respond To Issues Raised About Enhance
Clinical Trial |
| January 25 |
Over 30 New Studies of Oral Xeloda Featured at the 2008
Gastrointestinal Cancers Symposium |
| January 25 |
Denosumab Osteoporosis Study Met Primary and All Secondary Bone
Mineral Density Endpoints in a Head-to-Head Comparison with Weekly
Alendronate (Fosamax) |
| January 25 |
Nuvelo Announces Results from Phase 3 NAPA Program in Acute
Peripheral Arterial Occlusion |
| January 25 |
Phase I Study with uPA Inhibitor WX-UK1 Successfully Completed |
| January 25 |
MediGene to Present Recent Data Obtained in a Clinical Trial of
Oncolytic Virus NV1020 on the Occasion of the ASCO GI Symposium |
| January 25 |
MabThera Increases the Time Patients with the Most Common Form of
Adult Leukaemia Live Without Their Cancer Progressing |
| January 25 |
MabThera Meets Study Primary Endpoint in Improving Disease Symptoms
When Used as First Biologic Therapy in Patients with Rheumatoid
Arthritis |
| January 25 |
Oral Contraceptives Give Substantial Long-Term Protection Against
Ovarian Cancer |
| January 25 |
Stroke Prevention: Idraparinux Causes Significantly More Bleeding
Than Vitamin K Antagonists |
| January 28 |
BioLineRx Presents Pre-Clinical Data Demonstrating That BL-1021 Is
Safe and Effective in Treating Neuropathic Pain |
| January 28 |
EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study |
| January 28 |
Vasogen's Research Published in European Journal of Neuroscience |
| January 28 |
Acorda Therapeutics Announces Successful Thorough QT Study of
Fampridine-SR |
| January 28 |
Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of
Dimebon for Alzheimer's Disease in Second Quarter of 2008 |
| January 28 |
Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is
More Efficacious, Less Toxic than Gossypol in Animal Models |
| January 28 |
pSivida Pancreatic Cancer Study Results Released |
| January 28 |
Lipid Sciences Announces Positive HIV Program Results |
| January 28 |
Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in
Obese, Young Adults |
| January 28 |
Interim Safety Data Presented on Vectibix (Panitumumab) in
Combination with Standard Chemotherapy |
| January 28 |
Poniard Pharmaceuticals Announces Picoplatin Safety Data in
Colorectal Cancer |
| January 28 |
Studies Demonstrate Increased Efficacy of Erbitux in Metastatic
Colorectal Cancer Patients with KRAS Wild-Type Tumors |
| January 29 |
Compugen Announces In-Vivo Results for Two Peptide
Anti-Inflammatory and Cardio-Protective Drug Candidates |
| January 29 |
Viventia Biotech to Explore Strategic Alternatives - Reports
Positive Pivotal Phase III Interim Efficacy Data |
| January 29 |
Amgen Statement on Aranesp Manuscript in the Journal of Clinical
Oncology |
| January 29 |
Inverseon Announces Positive Phase IIa Asthma Study |
| January 29 |
Myriad Genetics Announces Completion of Phase 1 Trial of
Anti-Thrombin Drug MPC-0920 |
| January 29 |
Phase 1 Studies Show Promise of QuatRx's Novel Compound,
Sobetirome, for Lowering LDL Cholesterol Levels |
| January 29 |
Ardea Biosciences to Present Preclinical Data on Three HIV
Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual
Conference on Retroviruses and Opportunistic Infections |
| January 29 |
Surface Logix Achieves Objectives With SLx-4090 in Phase 2a
Clinical Trial |
| January 29 |
Pro-Pharmaceuticals Phase II Trial Shows Davanat Improves Median
Progression Free Survival with Fewer Side Effects as Compared to
Recent Similar Studies |
| January 29 |
APR Applied Pharma Research s.a. (“APR”) and Labtec
GmbH (“Labtec”) Announce the Successful Completion of
the Pilot Bioequivalence Study of Their Donepezil RapidFilm Further
Confirming the Validity and Adaptability of This Innovative
Proprietary Technology |
| January 29 |
DOR BioPharma Reports Achievement of Two-Year Stability Milestone
for RiVax, its Vaccine Against Ricin Toxin |
| January 29 |
Accentia Biopharmaceuticals Announces that Revimmune is Profiled in
Hopkins Medicine Magazine |
| January 30 |
Therapeutic DNA Vaccine Delivery via Inovio's Electroporation
Technology Featured in Nature Reviews Cancer |
| January 30 |
New Class of Highly Selective 5-HT4 Receptor Agonists Provides the
Next Generation of GI Treatments |
| January 30 |
Argos Therapeutics Publishes Novel Approach to Amplifying HIV Genes
for Personalized Immunotherapy Treatments for HIV |
| January 30 |
91 Percent of Oncologists Polled Report Adverse Patient Events as
Result of CMS National Coverage Decision on ESAs |
| January 30 |
Kidney Cancer Drug Attacks a Major Type of Acute Myeloid Leukemia |
| January 30 |
Phosphagenics Reports Superior Pre-clinical Cholesterol Results
from APA-01 and Atorvastatin Combination |
| January 30 |
Historic Breakthrough in Fighting Children's Batten Disease as
China Stem Cells Give New Lease on Life to 6 Year Old California
Boy |
| January 30 |
Intensive Insulin Therapy Protects Kidneys In Critically Ill
Patients |
| January 30 |
Babies Excrete Vaccine-Mercury Quicker than Originally Thought |
| January 31 |
ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia
HIV Pathogenesis Conference |
| January 31 |
Kiadis Pharma Announces Successful Completion of Rhitol Phase II
Clinical Study |
| January 31 |
JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients |
| January 31 |
AMAG Pharmaceuticals Provides Additional Clinical Information on
Ferumoxytol as an Intravenous Iron Replacement Therapeutic in
Chronic Kidney Disease Patients |
| January 31 |
Stentys Bifurcated Stent is Successfully Implanted for the First
Time at the Rotterdam ThoraxCenter |
